←
Mike Thompson, MD, PhD, FASCO148,395 posts
Mike Thompson, MD, PhD, FASCO avatar✓

Mike Thompson, MD, PhD, FASCO ✓

@mtmdphd

VP Hematology (TIME) @TempusAI #PrecisionMedicine #mmsm #lymsm #MDSsm #leusm #CCC19 @COVID19nCCC @ASCO COI: coi.asco.org/share/RBB-TT6R/…

◷ Joined September 2010▧ 18,883 Photos and videos
Shebli Atrash, MD, MS, FACP avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Shebli Atrash, MD, MS, FACP@AtrashShebli·43m

694 NDMM patients, one message: hyperdiploid myeloma is not one risk group. A modal count >49 and trisomy 3 predicted longer OS and PFS, and the ASCT OS benefit was limited to low-risk HRD with >49 chromosomes (BJH). PMID 42760862 #mmsm #myeloma #MedTwitter #MedEd

Post attachment
Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰@szusmani·Nov 16

Genomic instability: A potential predictor of immunotherapy resistance An important translational study linking genomic instability with treatment outcomes. DLP+ single-cell WGS analyzed 5,454 cells from 14 MM samples, with validation in 96 additional samples. The investigators identified two biological groups: • Genomically stable disease. • Genomically unstable disease, characterized by subclonal diversification, whole-genome doubling, convergent evolution, telomeric erosion and complex structural variants. Clinical observations were striking: • All 4 genomically unstable NDMM patients failed to achieve MRD negativity and progressed within 30 months. • None of 7 genomically stable patients progressed after 7 years. • In a small anti-BCMA bispecific validation cohort, genomic instability was associated with rapid progression. Could genomic instability become a clinically relevant biomarker of immunotherapy resistance? onlineprogram.hematology.org… 13/17 #ASH26 #mmsm

Shebli Atrash, MD, MS, FACP avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Shebli Atrash, MD, MS, FACP@AtrashShebli·Nov 17

Fat pad beats marrow for confirming AL amyloidosis: pooled sensitivity 77% vs 55% across 31 studies (Blood Advances meta-analysis). Both together reached 89% in a Mayo series. A simple aspirate can spare many an organ biopsy. PMID 42696041 #mmsm #myeloma #MedTwitter #MedEd

Post attachment
Tempus avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Tempus@TempusAI·Nov 11

Next week, Tempus will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society Annual Meeting (November 18–21). In rare diseases like sarcoma, small patient populations have historically created barriers to research. By leveraging our multimodal library, which includes real-world data from more than 45,000 patients across 615 rare and ultra-rare cancer types, our team is uncovering novel insights into rare mesenchymal tumors to advance precision oncology. Read the full announcement to learn more: tempus.co/4zKUQww #CTOS2026

Post attachment
Tempus avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Tempus@TempusAI·Nov 11

Our CEO and Founder @lefkofsky recently joined @MTSlive to discuss the evolving role of AI in clinical care as patients increasingly consult #GenAI tools with their own health data. Over the next 3 to 5 years, healthcare systems must equip physicians with the same caliber of advanced, intelligent technology to support clinical decision-making.

1:41
Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰@szusmani·Nov 16

Sonrotoclax: Targeting BCL2 in t(11;14) myeloma BCL2 remains an attractive therapeutic vulnerability in t(11;14) MM. Phase Ib/II sonrotoclax + daratumumab + dexamethasone (SDd) study (n=72). Median 3 prior lines; 56% triple-class exposed and 22% triple-class refractory. Among 70 response-evaluable patients: • ORR: 87%. • ≥VGPR: 59%. • ≥CR: 23%. • Median time to response: 1 month. • 12-month PFS: 69%. Grade 3/4 neutropenia: 28%. Grade 3/4 infections: 21%. No treatment-related discontinuations due to sonrotoclax. A compelling targeted strategy for molecularly selected MM. onlineprogram.hematology.org… 9/17 #ASH26 #mmsm

Ankit kansagra avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Ankit kansagra@kansagraMD·Nov 16

Most of us wait for relapse after CAR-T. The Penn group is asking why wait. Adam Cohen presented the updated STEM trial at #IMS26: cevostamab consolidation starting 10 to 12 weeks after commercial cilta-cel or ide-cel. 27 pts, 74% triple-class refractory, 41% with 2 or more high-risk features, 19% with EMD. At 1 yr post CAR-T: 24 of 27 in sCR, 25 MRD-neg at 10^-5, 23 at 10^-6. Cohen calls it 89% sustained MRD-neg CR, with "promising" 2-yr PFS. - The logic is good. FcRH5 is a different target, so a BCMA-escape clone has less room to hide, and you're hitting the disease when burden is at its lowest - The cost is cytopenias stacked on post-CAR-T cytopenias. Neutropenia 78% (48% G3/4), lymphopenia 67% G3/4. Seven pts held doses, six dropped to 90 mg - In the 2025 interim, both step-up doses came with a 48-hr admission. That's a site capacity issue as much as a toxicity one The bigger challenge is translational. Single arm, 27 pts, and the comparator in our heads is cilta-cel alone, where a lot of pts are already MRD-neg at 1 yr. Without a control we can't seperate what cevo added from what the CAR-T was doing anyway. Good news: the team says a multicenter randomized phase 2 is in development, which is excatly the right next step. If we can pick out the pts heading for early relapse and consolidate only them, this gets a lot easier to justify. #CARTcell #Myeloma #IMS26

Post attachment
Jasmine Kamboj, MD, FASCO avatar
⟳ Mike Thompson, MD, PhD, FASCO retweeted
Jasmine Kamboj, MD, FASCO@JasmineKambojMD·Nov 15

Do you have iron deficiency? Shout out to some Hematology friends (Dr Ariela Marshall of @UMNews) who are raising awareness on the updated @ASH_hematology guidelines on iron deficiency for ferritin threshold: ✅ infants/ children (9mo to 4 yrs), update suggests cutoff </= 20 Ng/ml instead of 12, for IDA ✅adults, less than or equal to 30 Ng/ml instead of 15. ✅adults w signs/ symptoms or ongoing risk factors a/w IDA, cut off off 50 ✅for menstruating individuals cut off less than/ equal to 30, instead of 15;; and folks w heavy menstrual bleeding/ abnormal uterine bleeding/ upcoming surgery/ planning pregnancy, threshold of less than/ equal to 50 Ng/ml ✅for pregnant individuals, threshold of less than/ equal to 30 Ng/ml— for preg individuals de anemia or sign/symp, threshold of 50 may be appropriate Plz check em out for yourself and your patients.. Too often we ignore our own symptoms or our patients symptoms, and push ourselves through fatigue, headaches and exhaustion.. everyone deserves to feel iron replete 💕🤗🙏 ashpublications.org/bloodadv… Thank you! 🙏 @ASCO @HemOncFellows @HemOncWomenDocs @hemeoncfellow @SocietyofHemOnc @MayoHemeOnc @YaleHemOnc @DanaFarber @yuan_ruiling @OncBrothers @oncodaily @myESMO @ASCOPost @oncology101_org @Dr_AmerZeidan @AmerMedicalAssn @oncologyCOA @VincentRK @MayoCancerCare @MayoMedEd @IMG_Oncologists @CancerGridIndia @AORTIC_AFRICA @uicc @WHO

Post attachment